Abstract

BackgroundBordetella pertussis is the main agent of whooping cough. Vaccination with acellular pertussis vaccines has been largely implemented in high-income countries. These vaccines contain 1 to 5 antigens: pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN) and/or fimbrial proteins (FIM2 and FIM3). Monitoring the emergence of B. pertussis isolates that might partially escape vaccine-induced immunity is an essential component of public health strategies to control whooping cough.AimWe aimed to investigate temporal trends of fimbriae serotypes and vaccine antigen-expression in B. pertussis over a 23-year period in France (1996–2018).MethodsIsolates (n = 2,280) were collected through hospital surveillance, capturing one third of hospitalised paediatric pertussis cases. We assayed PT, FHA and PRN production by Western blot (n = 1,428) and fimbriae production by serotyping (n = 1,058). Molecular events underlying antigen deficiency were investigated by genomic sequencing.ResultsThe proportion of PRN-deficient B. pertussis isolates has increased steadily from 0% (0/38) in 2003 to 48.4% (31/64) in 2018 (chi-squared test for trend, p < 0.0001), whereas only 5 PT-, 5 FHA- and 9 FIM-deficient isolates were found. Impairment of PRN production was predominantly due to IS481 insertion within the prn gene or a 22 kb genomic inversion involving the prn promoter sequence, indicative of convergent evolution. FIM2-expressing isolates have emerged since 2011 at the expense of FIM3.ConclusionsB. pertussis is evolving through the rapid increase of PRN-deficient isolates and a recent shift from FIM3 to FIM2 expression. Excluding PRN, the loss of vaccine antigen expression by circulating B. pertussis isolates is epidemiologically insignificant.

Highlights

  • Bordetella pertussis is the main causative agent of whooping cough, a severe respiratory infection in humans [1]

  • The acellular pertussis vaccines (aPV) formulations contain one to five antigenic proteins of B. pertussis corresponding to virulence factors, including pertussis toxin (PT) and optionally filamentous haemagglutinin (FHA), pertactin (PRN) and fimbrial proteins (FIM2 and FIM3)

  • Since 1996, the French surveillance system of whooping cough is built on a sentinel hospital-based voluntary surveillance network (RENACOQ), coordinated by Public Health France, and is estimated to capture approximately one third of paediatric cases hospitalised with pertussis disease [17]

Read more

Summary

Introduction

Bordetella pertussis is the main causative agent of whooping cough, a severe respiratory infection in humans [1]. Whole-cell pertussis vaccines (wPV) have been used on a large scale since 1959 and elicited a very strong decrease in disease incidence [2] Despite their effectiveness, the use of wPV raised concerns about their side effects and production quality and they were replaced in many high-income countries by acellular pertussis vaccines (aPV). The aPV formulations contain one to five antigenic proteins of B. pertussis corresponding to virulence factors, including pertussis toxin (PT) and optionally filamentous haemagglutinin (FHA), pertactin (PRN) and fimbrial proteins (FIM2 and FIM3). Vaccination with acellular pertussis vaccines has been largely implemented in high-income countries These vaccines contain 1 to 5 antigens: pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN) and/or fimbrial proteins (FIM2 and FIM3). Aim: We aimed to investigate temporal trends of fimbriae serotypes and vaccine antigen-expression in B. pertussis over a 23-year period in France (1996–2018). Excluding PRN, the loss of vaccine antigen expression by circulating B. pertussis isolates is epidemiologically insignificant

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call